Drug intelligence / Profile preview

VRC-HIVDNA009-00-VP

Development stage: Phase 2
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

VRC-HIVDNA009-00-VP is a multiclade HIV-1 DNA plasmid vaccine developed by the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine is a mixture of four DNA plasmids: one encoding a Gag-Pol-Nef fusion protein from HIV-1 clade B, and three encoding modified Envelope (Env) glycoproteins from clades A, B, and C. These clades represent approximately 90% of new HIV infections globally. The vaccine is designed to elicit both humoral (antibody) and cellular (CD4+ and CD8+ T cell) immune responses against HIV. It has been evaluated in clinical trials as a standalone preventive vaccine, a therapeutic vaccine in HIV-infected individuals on antiretroviral therapy, and as a priming agent in prime-boost regimens, frequently followed by an adenoviral vector boost such as VRC-HIVADV014-00-VP.

Other names: VRC 004VRC004VRC-004multiclade HIV-1 DNA vaccineGag-Pol-Nef-multiclade Env DNA vaccine

Targets

Human immunodeficiency virus type 1 reverse transcriptaseNef (HIV-1 Nef)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)Gag (HIV-1 Gag polyprotein)

Beyond the preview

Go deeper on VRC-HIVDNA009-00-VP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRC-HIVDNA009-00-VP.

Explore the full profile